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Surrogate Endpoints in Second-Line Trials of 
Targeted Agents in Metastatic Colorectal Cancer: 
A Literature-Based Systematic Review and Meta-Analysis
Meta-Analysis
Purpose
The purpose of this study was to evaluate progression-free survival (PFS) and objective 
response rate (ORR) as surrogate endpoints of overall survival (OS) in modern clinical trials
investigating the efficacy of targeted agents in the second-line treatment of metastatic col-
orectal cancer (mCRC). 
Materials and Methods
A systematic search of literature pertaining to randomized phase II and III trials evaluating
targeted agents as second-line treatments for mCRC was performed. The strength of the cor-
relation between both PFS and ORR and OS was assessed based on the Pearson’s correlation
coefficient (R) and the coefficient of determination (R2). 
Results
Twenty trials, including a total of 7,571 patients, met the search criteria. The median dura-
tion of post-progression survival (PPS) was 7.6 months. The median differences between
experimental and control arms were 0.65 months (range, –2.4 to 3.4) for the median PFS
and 0.7 months (range, –5.8 to 3.9) for the median OS. PFS and ORR showed moderate
(R=0.734, R2=0.539, p < 0.001) and poor correlation (R=0.169, R2=0.029, p=0.476) with
OS, respectively. No differences between anti-angiogenic agents and other drugs were 
evident.
Conclusion
Targeted agents investigated in the second-line treatment of mCRC provided minimal PFS
gains translating into modest OS improvements. Considering both the moderate correlation
between PFS and OS and the short duration of PPS, the OS should remain the preferred
primary endpoint for randomized clinical trials in the second-line treatment of mCRC. 
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Introduction
The choice of the primary endpoint is essential to the 
design of clinical trials. While overall survival (OS) actually
reflects the ultimate goal of cancer treatments, and is there-
fore regarded as a preferred choice in the metastatic setting,
the surrogacy of other endpoints was investigated in differ-
ent malignancies. The identification of valuable surrogate
endpoints, which are potentially reachable in a shorter time
and with a lower number of patients, would allow notable
decreases in trial duration, thus expediting drug develop-
ment and making new options more rapidly available for
cancer patients. 
With regard to metastatic colorectal cancer (mCRC), the 
reliability of response parameters and progression-free sur-
vival (PFS) during first-line treatments as surrogate end-
points of OS has previously been evaluated. While surrogacy
for OS has not been formally proven for the objective 
response rate (ORR) [1,2], nor for the new parameter of early
tumor shrinkage [3], PFS was shown to achieve strong sur-
rogacy for OS in trials conducted before the introduction of
targeted agents [2,4]. In a recently published literature-based
analysis of surrogate endpoints in second-line treatment for
mCRC, PFS was considered a reliable surrogate for OS [5].
However, about half of the clinical trials included in that sys-
tematic review compared chemotherapy only regimens,
without targeted agents. In recent years, the adoption of new
drugs with different mechanisms of action and the availabil-
ity of multiple effective treatments after progression has 
enabled extension of post-progression survival (PPS), and is
challenging the role of PFS as a surrogate of OS. Even though
a previous analysis suggested that in modern trials OS could
be better associated with PPS than with PFS [6], significant
surrogacy for PFS was confirmed, justifying its adoption as
a primary endpoint in first-line studies in mCRC [7-9]. How-
ever, in a systematic review and meta-analysis of 101 ran-
domized controlled trials conducted in advanced colorectal
cancer, none of the surrogate endpoints considered (ORR,
PFS, time to progression) achieved the level of evidence 
required to qualify correlation levels as high or excellent by
means of common surrogate evaluation tools [10]. 
In the last few years, several targeted agents have been
tested in second- and further-lines of treatment and shown
to produce significant, although only incremental, gains in
OS. Today, as previously shown for first-line treatments, the
effectiveness of new drugs in third and later lines might 
dilute the impact of second-line regimens on OS. Moreover,
the frequent adoption of cross-over designs, especially in
clinical settings with no other effective options, deeply influ-
ences OS findings, making the choice of earlier endpoints 
extremely appealing. 
The present literature-based analysis was conducted to
evaluate the correlation of both PFS and ORR with OS in
modern clinical trials investigating the efficacy of targeted
agents in the second-line treatment of mCRC. Since the rele-
vance of surrogate endpoints may differ according to the
mechanisms of action of investigated drugs, this analysis also
separately evaluated the correlation of PFS and ORR with OS
for anti-angiogenic agents relative to drugs with other mech-
anisms of action.
Materials and Methods
1. Literature search 
A literature search was performed in October of 2015 to
identify all randomized phase II and phase III trials evaluat-
ing molecular-targeted agents as second-line treatments for
advanced colorectal cancer. The literature search was per-
formed using PubMed, and the following keywords: “(col-
orectal cancer) AND (pretreated OR “previously treated” OR
“second line”) AND random*”. Following a comment by a
reviewer, a second search “(colorectal cancer) AND (pre-
treated OR “previously treated” OR “second line”) AND ran-
domized controlled trial [Publication type]” was performed
to verify that all records included in the latter search had 
already been included in the former search. References of the
selected articles were also checked to identify further eligible
trials. Moreover, the proceedings of the American Society of
Clinical Oncology (ASCO) annual meeting and European 
Society of Medical Oncology meeting were searched from
2012 onwards for relevant abstracts. When more than one 
report describing the results of the same trial was available,
the most recent information (corresponding to a longer fol-
low-up and a higher number of events) was utilized. Trials
randomizing patients to receive or not receive an anti–epi-
dermal growth factor receptor monoclonal antibody were 
included only if results in the RAS (or at least KRAS) wild-
type subgroup were available.
2. Data abstraction
For each eligible trial, the following data were collected, if
available:
- Study phase (II or III).
- Details of study treatment: control arm; experimental arm
(or arms if more than one experimental treatment). Con-
trol arms were identified based on the null hypothesis of
the statistical design underlying each single trial as 
reported in full manuscripts or presented abstracts.
- Details regarding cross-over (administration of experi-
mental treatment to patients assigned to the control arm
after disease progression). 
- Study primary endpoint.
- Patients’ enrolment: number of enrolled patients, number
of patients assigned to control arm, number of patients
assigned to experimental arm.
- ORR: proportion of objective responses in the control
arm, proportion of objective responses in the experimen-
tal arm; relative risk of response (calculated as the ratio
between the response rate in the experimental arm and
in the control arm).
- PFS: median PFS in the control arm, median PFS in the
experimental arm, hazard ratio (HR) with 95% confidence
interval, p-value. 
- OS: median OS in the control arm, median OS in the 
experimental arm, HR with 95% confidence interval, 
p-value. 
- PPS: absolute PPS was calculated as the difference 
between median OS and median PFS; relative PPS was
calculated as the ratio between median PPS and median
OS. For instance, in a treatment arm with a median PFS
of 4 months and a median OS of 10 months, absolute PPS
was 6 months (10–4) and relative PPS was 60% (6/10). 
For trials with more than two treatment arms, multiple
records were completed, one for each comparison. 
Two investigators independently abstracted the data from
the publications, and subsequently compared their results.
All data were checked for internal consistency, and disagree-
ments were resolved by discussions among the investigators.
3. Statistical analysis
To analyze the correlation between PFS and OS, two dif-
ferent regression analyses were performed: (1) correlation
between the HR for PFS and HR for OS and (2) correlation
between the difference in median PFS and the difference in
median OS between arms. Similarly, to analyze the correla-
tion between ORR and OS, two different regression analyses
were performed: (1) correlation between the relative risk of
response and HR for OS and (2) correlation between the dif-
ference in ORR between arms and the difference in median
OS between arms. 
All analyses were weighted by the sample size of each
comparison. In the case of trials with two experimental arms
and a single control arm [11-14], two separate comparisons
were analyzed (each experimental arm versus the control
arm). However, to avoid double-counting of the patients 
enrolled in the control arm and the risk of clustered data,
each comparison was given a lower weight that was obtained
by equally dividing the total number of patients of the con-
trol arm between the two comparisons.
In each analysis, the strength of the correlation was evalu-
ated by calculating the Pearson’s correlation coefficient (R)
and the coefficient of determination (R2). Pearson’s R is a sim-
ple measure of the linear correlation between two variables,
giving a value between 1 and −1, where 1 is a total positive
correlation, 0 is the absence of correlation, and −1 is a total
negative correlation. The coefficient of determination is such
that 0 ≤ R2 ≤ 1. Although there are no specific cut-offs to 
define a moderate or strong correlation, a higher R2 score 
indicates a stronger association. 
Correlations were graphically described by bubble plots,
where each bubble represents a comparison between one 
experimental arm and one control arm, with bubble size pro-
portional to the sample size of each comparison. As all analy-
ses were weighted by the sample size of each trial/com-
parison, weighted least-squares regression lines were calcu-
lated and reported in each graph. 
Exploratory subgroup analyses were performed according
to the type of experimental drug tested (anti-angiogenic
drugs vs. other drugs). 
Statistical analyses were conducted using SPlus (S-PLUS
6.0 Professional, release 1, Insightful Corporation, Seattle,
WA) and SPSS ver. 22.0 (IBM Corp., Armonk, NY). Graphs
were realized using SigmaPlot (Systat Software, San Jose,
CA). For all analyses, a p-value of < 0.05 was considered sta-
tistically significant. 
Results
1. Trial characteristics
Overall, 20 trials were identified (Fig. 1), nine phase III tri-
als and 11 randomized phase II trials (Table 1) [11-30]. A total
of 7,571 patients were enrolled in these trials, and the median
number of enrolled patients was 197 (range, 75 to 1,226). The
primary endpoint was PFS in 12 trials (60%) [11-15,18,19,
21-24,30], OS in six trials (30%) [16,20,26-29] and ORR in one
trial (5%) [17]. In one trial (5%), PFS and OS were co-primary
endpoints [25]. Four trials had three treatment arms, with
two comparisons between each of the two experimental arms
and the single control arm [11-14]. In one trial, there were
four arms (two experimental arms and two control arms)
with two separate comparisons [15]. Overall, 25 comparisons
were recorded (Table 1).
Information regarding cross-over was not available for
most reports (19 out of 25 comparisons). In the six reports
with details about subsequent administration of experimen-
tal drugs (or drugs with the same mechanism of action) in
patients assigned to control arms, cross-over was quite neg-
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ligible (median proportion, 3.5%; range, 0% to 32%).
2. Outcomes
Based on all comparisons with available information, the
median value of the OS in the 25 experimental arms was 13.1
months (range, 9.6 to 21.4), and the median value of the OS
in the control arms was 13.9 (range, 8.8 to 19.8). The median
difference between experimental and control arms was equal
to 0.7 months (range, –5.8 to 3.9). In the 21 comparisons with
available information, the median HR for OS was 0.90 (range,
0.69 to 1.57).
Based on all comparisons and available information, the
median value of the PFS in the 24 experimental arms was 6.4
(range, 2.1 to 8.5), and the median value of the median PFS
in the control arms was 5.4 (range, 2.4 to 9.0). The difference
in median values between the experimental and control arms
was equal to 0.65 months (range, –2.4 to 3.4). In the 23 com-
parisons with available information, the median HR for PFS
was 0.85 (range, 0.61 to 1.45). 
Based on all available information regarding the median
OS and median PFS, the median absolute PPS in the experi-
mental arms was 7.6 months (range, 4.4 to 14.6). The relative
PPS (expressed as a proportion of OS) ranged from 43.4% to
82.3%, with a median value of 55.7%. In the control arms, the
median absolute PPS was 7.6 months (range, 3.6 to 14.3) and
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Fig. 1.  Outline of the search flow diagram. Selection process for randomized controlled trials included in the analysis. ASCO,
American Society of Clinical Oncology; ESMO, European Society of Medical Oncology; ECCO, European Cancer Organiza-
tion; GI, gastrointestinal; EGFR, epidermal growth factor receptor.
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expressed as a proportion of OS, while the relative PPS
ranged from 40.9% to 75.0%, with a median value of 60.7%
(Table 2). Fig. 2 describes the median PFS and median PPS
based on all comparisons included in the analysis, scattered
by the type of experimental drug (anti-angiogenics vs. other
drugs). 
Based on all available information, the median ORR in the
25 experimental arms was 19% (range, 5% to 48%), and the
median ORR in the control arms was 12% (range, 0% to 35%).
The median difference in the ORR between experimental and
control arms was equal to 2.6% (range, –12.3% to 31%). The
median relative risk of response was 1.24 (range, 0.59 to 7.00).
3. Association between PFS and OS
Information regarding HRs for PFS and OS was available
for 21 trials. Overall, there was a moderate correlation
(R=0.734, R2=0.539, p < 0.001) (Table 3, Fig. 3A). The slope of
the regression line (0.739) suggests that a 0.1 improvement
in PFS HR corresponds to a 0.074 improvement in OS HR.
The correlation between HRs for PFS and OS was significant
for the 13 comparisons investigating anti-angiogenic drugs
(R=0.655, R2=0.429, p=0.015) and the eight comparisons 
investigating other drugs (R=0.857, R2=0.734, p=0.007) (Table 3,
Fig. 3B and C). There was no significant interaction between
drug categories and the correlation between HRs for PFS and
OS (p=0.775) (Table 3). 
Similar results were observed when the correlation 
between PFS and OS was analyzed for both endpoints based
on the difference in median values between study arms. This
information was available for 24 comparisons (Table 3, 
S1 Fig. A). Overall, there was a moderate correlation between
PFS and OS (R=0.632, R2=0.399, p < 0.001). The slope of the
regression line (1.065) suggests that a one month increase in
the difference in median PFS corresponds to a 1.06 month 
increase in the difference in median OS. The correlation 
between PFS and OS based on the difference in median val-
ues between study arms was significant for both the 16 com-
parisons evaluating anti-angiogenic drugs (R=0.651, R2=
0.423, p=0.006) and the eight comparisons evaluating other
drugs (R=0.724, R2=0.525, p=0.042) (Table 3, S1 Fig.  B and C).
The interaction between drug categories and the correlation
between PFS and OS was not significant (p=0.110) (Table 3). 
4. Association between ORR and OS
Information regarding the relative risk of objective 
response and HR for OS was available for 20 comparisons.
Overall, there was a weak correlation that was not statisti-
cally significant (R=0.169, R2=0.029, p=0.476) (Table 4, 
Fig. 4A). The correlation between relative risks of response
and HRs for OS was not significant for the 12 comparisons
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evaluating anti-angiogenic drugs (R=0.361, R2=0.131,
p=0.249) or the eight comparisons evaluating other drugs
(R=0.441, R2= 0.195, p=0.274) (Table 4, Fig. 4B and C). There
was no significant interaction between drug categories and
the association between the relative risk of response and the
HR for OS (p=0.654) (Table 4). 
Information regarding the difference in ORR and the 
median OS between study arms was available for 25 com-
parisons. Based on these parameters, a weak correlation was
found (R=0.345, R2=0.119, p=0.092) (Table 4, S2 Fig. A). The
correlation between response and OS considering the differ-
ence in ORR and in the median OS between study arms was
weak to moderate for the 16 comparisons of anti-angiogenic
drugs (R=0.522, R2=0.272, p=0.038) and the nine comparisons
investigating other drugs (R=0.632, R2=0.399, p=0.068) (Table
4, S2 Fig. B and C). The interaction between this correlation
and drug categories was not significant (p=0.904) (Table 4).
Discussion
Different targeted agents recently gained approval for the
second-line treatment of mCRC based on relatively small 
absolute gains in OS. Nevertheless, the impact of these treat-
ments on the overall prognosis of mCRC patients is rather
limited [31], and the improvements achieved with novel
treatments are below the expectations. Overall, the results
from the 20 second-line trials included in the present analysis
indicate that the median PFS accounts for 44% and 39% of
the median OS in the experimental and control arms, respec-
tively. Although PPS will probably increase in the future, the
median absolute duration of PPS in our series was quite short
(7.6 months) due to the availability of new effective options
in later lines. These findings demonstrate that, at least for the
timeframe in which the trials included in this analysis were
conducted, the impact of third- and further-line treatments
on mCRC patients’ prognosis was rather modest.
We systematically reviewed the inherent literature to focus
on clinical trials investigating the efficacy of targeted agents
in the second-line treatment of mCRC to assess the correla-
tion of earlier endpoints, PFS and ORR, with OS, and to 
Chiara Cremolini, Surrogate Endpoints in Second-Line Trials in mCRC
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analyze their surrogacy for OS. While a similar approach was
previously pursued by other groups [5], we chose to restrict
our analysis to modern trials of targeted agents to put our
results in the context of ongoing and future studies in this
setting. In fact, previous studies have clearly shown that the
reliability of surrogate endpoints must be properly verified
within the context in which these endpoints should be sub-
sequently adopted. Namely, out of the 23 trials included in
the systematic review by Giessen et al. [5], as many as nine
trials compared chemotherapy-only treatment regimens
without targeted agents. Furthermore, those authors empha-
sized that a re-analysis according to the different mecha-
nisms of drug activity should be conducted as soon as a
larger set of trials was available. Therefore, we conducted an
exploratory subgroup analysis to assess potential differences
in surrogacy according to the targeted agents’ mechanisms
of action (mainly anti-angiogenic versus directed against
other cellular targets), as already suggested in first-line stud-
ies [7]. This exploratory subgroup analysis did not produce
clear evidence of an interaction between the mechanism of
action and surrogacy for the endpoints considered. A clear
limitation of this study is that, while the anti-angiogenic
group is clearly defined, the “other drugs” group includes
agents with heterogeneous mechanisms of action.
Although our analysis has several limitations, we observed
a moderate correlation between PFS and OS, while a poor
correlation between ORR and OS was reported, with no rel-
evant differences according to the drugs’ mechanisms of 
action. It should be noted that, after demonstrating a similar
moderate correlation between PFS and OS, other authors
concluded that PFS may be considered an appropriate sur-
rogate endpoint in second-line treatments for mCRC [5].
However, when specifically focused on targeted agents, our
results can affirm that OS remains the preferred primary
endpoint for randomized clinical trials in this setting. How-
ever, the following considerations should be taken into 
account to justify this interpretation. First, only small median
absolute gains in PFS were reported in statistically positive
trials, making it rather difficult to translate these results into
clinically relevant improvements in OS. According to the
ASCO perspective, improvements of at least three months in
median OS (primary endpoint) or median PFS (secondary
endpoint) should be regarded as meaningful for mCRC 
patients experiencing disease progression with all prior ther-
apies, or not eligible for standard options [32]. However, the
slope of the regression line in our analysis suggests that small
benefits in PFS, on average, are going to translate into modest
OS differences. These achievements can only be regarded as
clinically relevant if supported by solid improvements in
quality of life, which were rarely assessed in the available lit-
erature. While the lack of molecular criteria able to positively
select patients more likely to benefit from targeted agents
may explain the present findings, the introduction of “preci-
sion medicine” principles into clinical research will likely
change the present scenario.
Secondly, since the duration of PPS is quite short, the
adoption of PFS instead of OS as a primary endpoint would
not lead to a dramatic decrease in the duration, sample size,
and financial costs of trials, or to a considerable acceleration
of a drug’s development. However, the recent availability of
new effective drugs in later lines of treatment, i.e., after fail-
ure of second-line agents, will probably prolong the duration
of PPS. Moreover, only 30%-40% of patients included in sec-
ond-line clinical trials actually receive treatments after pro-
gression. Hopefully, this percentage will increase in response
to the introduction of highly effective targeted strategies in
earlier lines of treatment. Both of these aspects may further
weaken the correlation between the PFS and OS and lead to
reconsideration of the surrogacy of second-line PFS in cur-
rently ongoing and future trials.
In other settings, cross-over has been shown to play a rel-
evant role in the correlation between PFS and OS. As 
expected, if a high proportion of patients assigned to the con-
trol arm receive the experimental drug after disease progres-
sion (or a drug with the same mechanism of action), the
difference between treatment arms might be significantly 
decreased [33]. In the present analysis, information regarding
the possibility of cross-over according to study protocol and
the proportion of patients actually receiving cross-over was
not available in most trials; however, as detailed in the 
Results, this proportion was quite low in all trials for which
this information was available. 
A limitation of the present meta-analysis is that it is not
based on individual patient data, but rather on data extracted
from the publications (or, in some cases, from meeting pre-
sentations); therefore, we could only estimate trial-level, but
not individual patient-level surrogacy. However, even if
analysis of the individual patient-level association can lead
to an estimation of how much the endpoints are likely to be
causally linked to each other, the trial-level analysis remains
useful to show the proportion of the OS effect captured by
surrogate endpoints [34]. Although intrinsically limited, this
information could facilitate the interpretation of trial results
and design of future trials in this specific setting.
In conclusion, caution is needed when assessing the sur-
rogacy of potentially useful endpoints and supporting their
adoption in phase III clinical trials. Notably, only five out of
36 drugs approved by the U.S. Food and Drug Administra-
tion on the basis of surrogate endpoints were able to provide
an OS benefit in subsequent trials [35]. Based on our data, OS
should be the primary endpoint for registrative phase III tri-
als in the second line treatment of mCRC. Given its moderate
surrogacy for OS, PFS may be adopted in earlier steps of
drug development.
Chiara Cremolini, Surrogate Endpoints in Second-Line Trials in mCRC
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